SGLT2 inhibitors — session overview
- From glucose lowering to cardio-renal protection
- Why renal physiology explains the broader clinical effects
- Diabetes, heart failure and CKD as overlapping care pathways
SGLT2 inhibitors started as diabetes drugs and became some of the most important medicines in cardiology and nephrology. Dr Anzal Qurbain covers the mechanism, the landmark DAPA-HF, EMPEROR-Reduced, a
This on-demand webinar is a recorded episode from the Drug Class Explainers series.
Listen to the full session below and earn 0.5 CPD hours upon completion.
SGLT2 inhibitors started as diabetes drugs and became some of the most important medicines in cardiology and nephrology. Dr Anzal Qurbain covers the mechanism, the landmark DAPA-HF, EMPEROR-Reduced, and DAPA-CKD trials, and the critical sick day rules every clinician must know — including the risk of euglycaemic DKA.
Guidelines, mechanisms, trials and CPD connected to this webinar topic.
Get Diabetes / Metabolic webinar, podcast and CPD releases in your ClinicaliQ preferences.